Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2012  |  Volume : 8  |  Issue : 1  |  Page : 23--27

Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy


Daya Nand Sharma1, Goura Kisor Rath1, Rakesh Kumar2, Arun Malhotra2, Sunesh Kumar3, Jagadesan Pandjatcharam1, Sagar Maharjan2 
1 Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi 110029, India
2 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi 110029, India
3 Department of Gynecology and Obstetrics, All India Institute of Medical Sciences, New Delhi 110029, India

Correspondence Address:
Daya Nand Sharma
F-39, Ansari Nagar, New Delhi 110029
India

Purpose: To evaluate the role of positron emission tomography (PET) for predicting the clinical outcome of patients with recurrent cervical carcinoma following definitive radiation therapy (RT). Materials and Methods: Twenty two patients of post irradiated recurrent cervical carcinoma (PIRCC) were enrolled in this prospective study. 18-fluorodeoxyglucose (FDG) PET imaging was performed in each patient before the salvage therapy. The maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were measured and correlated with cumulative progression free survival (PFS). Results: Median age of patients was 42 years. Majority of patients had stage III disease at the initial presentation and all 22 patients had received prior definitive RT. The median recurrence free period was 11 months. Salvage therapy consisted of surgical resection or re-irradiation depending upon the various clinical and radiological factors. Median SUVmax was 5.8 (range 1.8-50.6) and median MTV was 43 cm 3 (range 5.8-243). The cumulative PFS for all patients was 20% at 30 months. The one-year PFS was 28% for patients with SUVmax value of >5.8 versus 42% for those with SUVmax value of <5.8 (P value 0.01). The one-year PFS was 43% for patients with MTV value of >43 cm 3 versus 45% for those with MTV value of <43 cm 3 (P value 0.8). Conclusion: Our preliminary experience has suggested that FDG uptake on PET scan can predict the clinical outcome of PIRCC patients. Further randomized studies may be conducted with large sample size and longer follow up to establish its definite predictive value.


How to cite this article:
Sharma DN, Rath GK, Kumar R, Malhotra A, Kumar S, Pandjatcharam J, Maharjan S. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy.J Can Res Ther 2012;8:23-27


How to cite this URL:
Sharma DN, Rath GK, Kumar R, Malhotra A, Kumar S, Pandjatcharam J, Maharjan S. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy. J Can Res Ther [serial online] 2012 [cited 2020 Aug 15 ];8:23-27
Available from: http://www.cancerjournal.net/article.asp?issn=0973-1482;year=2012;volume=8;issue=1;spage=23;epage=27;aulast=Sharma;type=0